Chimerix, Inc.
Nov 9, 2016

Chimerix to Present at Upcoming Investor Conferences

DURHAM, N.C., Nov. 09, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals to address unmet medical needs, today announced that M. Michelle Berrey, M.D., M.P.H, President and Chief Executive Officer of Chimerix, will present a corporate overview at the following upcoming conferences:

A live audio webcast of each presentation will be available on the Investor Relations section of Chimerix's website at www.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website www.chimerix.com.

CONTACT:

Investor Relations:



ir@chimerix.com

or

Will O'Connor

Stern Investor Relations

Will@sternir.com

212-362-1200



Media:



Becky Vonsiatsky

W2O Group

bvonsiatsky@w2ogroup.com

413-478-2003

Primary Logo

Source: Chimerix, Inc.

News Provided by Acquire Media